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Abstract 
Objectives 
According to clinical and comissioning guidelines for chronic rhinosinusitis (CRS), patients 
being referred to secondary care should have failed primary medical treatment with nasal 
douching (ND) and intranasal corticosteroids (INCS). The study objectives were to identify 
the rate of specific medical therapy in CRS patients and establish any differences in 
medication use, for both CRS and associated medical conditions, between CRS phenotypes. 
Design and setting 
Case-control study in a secondary care setting. 
Methods 
Participant-reported study-specific questionnaire capturing free text data on current 
medication use at the time of study entry. Qualitative interviews with 21 participants also 
explored their experience of CRS and its management. 
Particpants 
Patients with both without (CRSsNPs) and with polyps (CRSwNPs).  
Main outcome measures 
Reported use of CRS-related and non-related medications. 
Results 
Within a total of 1243 CRS participants, current INCS usage was low (18% in CRSwNPs, 12% 
in CRSsNPs); ND was being performed by only 1% of all participants. Bronchodilators and 
inhaled corticosteroids use was significantly higher in CRSwNPs participants (p < 0.0001). 
Antidepressants use was significantly higher in CRSsNPs (14% versus 7%, p < 0.0002). There 
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were no significant regional variations in rates of INCS use, nor any significant influence of 
social deprivation. 
Conclusions 
The current use of baseline medical therapy in CRS appears to be very low, representing a 
combination of poor patient compliance, possible ineffectiveness of treatment and a lack of 
familiarity with current guidelines amongst general practitioners and some ENT specialists. 
Work is needed to disseminate guidelines to all practitioners involved and reduce 
unnecessary burden on existing healthcare resources for this common condition by ensuring 
timely referral and definitive management. 
 
Background  
Chronic rhinosinusitis (CRS) is a common inflammatory disorder of the respiratory tract 
defined by the presence of either nasal blockage and/or nasal discharge as well as loss of 
smell and/or facial pain/pressure for 12 weeks or more; this must be corroborated with 
endoscopic findings (mucopus/polyps) and/or radiological findings (CT scan opacification in 
sinuses)1. CRS affects a significant proportion of the adult population with a recent 
European study suggesting a prevalence of 11% in the UK 2. Longitudinal data from the 
Clinical Practice Research Datalink (CPRD) shows that 1% these affected adults receive 
treatment from their GP each year with an average of 4 GP visits3, and additionally this 
includes prescription of multiple medications with 91% receiving an antibiotic prescription 4. 
There are no NICE guidelines and although international guidelines exist, 1, 5 familiarity and  
uptake of them is not quantified. These guidelines recommend both intranasal 
corticosteroids (INCS) and saline irrigation/nasal douching (ND), for which there are strong 
recommendations for use, based on recent Cochrane reviews 6-8. Hospital Episode Statistics 
(HES) Data shows that approximately 40,000 sinus operations are performed (mostly for 
CRS), in England and Wales each year, which is the progression of management when 
medical treatment in isolation has failed 9. A recent ENT-UK commissioning guideline 
underpins the need for adequate medical management and compliance with ND and INCS 
use for at least 3 months before referral to secondary care and possible surgical 
intervention10.  In a recent Canadian study it was demonstrated that only 20% of adult 
patients who received a diagnosis of CRS within the previous 3 years and had not undergone 
sinus surgery, had utilised their INCS indicating approximately 80% had failed to use a single 
unit of INCS and thus identifying a gap in the quality of care 11. Currently there are an 
estimated 120,000 secondary care outpatient encounters for CRS per year in England and 
Wales 12 and this could represent an unnecessary burden if primary medical treatment is 
not being best utilised; extrapolating the above Canadian data that 80% of patients failed to 
achieve this would translate to a cost of over £15 million in secondary care referrals. 
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The aim of this specific analysis of the data from the Chronic Rhinosinusitis Epidemiology 
Study (CRES) was to quantify the use of medications specific to CRS and for other co-
morbidities at a point of contact with secondary care and thus determine the degree of 
compliance with optimal medical management of CRS prior to that contact.  
Methods  
Study design and setting 
The CRES was approved by the Oxford C Research Ethics Committee (Ref: 07/H0606/100), 
sponsored by the University of East Anglia (UEA) and funded by the Anthony Long and 
Bernice Bibby Trusts. Details of the full methods used for the whole study can be seen in the 
overview publication13. In summary, the CRES aimed to identify differences in socio-
economic variables and quality of life between patients with chronic rhinosinusitis and 
healthy controls and was conducted as a prospective case-control multi-centre study across 
the UK involving 30 sites between 2007 and 2013; adoption of the study on to the NIHR 
portfolio in 2012 saw recruitment of over 600 participants in 1 year. Any patients presenting 
to secondary care ENT outpatient clinics and diagnosed with CRS (as defined by the criteria 
laid out in the European Position Paper on Rhinosinusitis and Nasal Polyps 1 (see above) by 
an Otorhinolaryngologist), were invited to complete the study questionnaire regardless of 
symptom or disease severity or duration, and regardless of any prior interventions. Control 
subjects were also recruited but do not form part of this specific analysis. 
 
Variables and data sources 
The study specific questionnaire (appendix 1) was anonymous and therefore no consent was 
taken but implied through participation, as approved by the ethics committee. Participant 
information leaflets were provided.  Patients were classified by sub group of CRS (CRSsNPs, 
CRSwNPs or allergic fungal rhinosinusitis (AFRS) by an Otorhinolaryngologist prior to 
completion of the questionnaire. Questionnaires were either completed before leaving the 
clinic or taken home and returned by post in Freepost envelopes. The returned 
questionnaires were then scanned into a database electronically but the electronic records 
were then checked by two members of the research team for accurate correlation with the 
paper questionnaire and for missing data. The return rate for questionnaires during the 
NIHR portfolio phase of the study was 66%. 
The study questionnaire included the question “Do you have any regular medications? 
Yes/No” followed by a free text box asking participants to list any current medication use.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The qualitative arm of the CRES was undertaken in 2012. This consisted of qualitative 
interviews with 21 patients with CRS were purposively selected to explore their experiences 
of CRS and its management. These patients were all recruited via the Rhinology clinic at 
James Paget University Hospital, Great Yarmouth. A thematic analysis of the transcripts was 
undertaken and the results from this study are published in full separately 14, 15 but results 
relevant to this analysis are considered here.  
 
Participants 
Patients were recruited at the first point of contact during outpatient consultation in 
secondary care, regardless of prior management in either primary or secondary care and 
regardless of prior surgical intervention. They were classified by sub group of CRS (CRSsNPs, 
CRSwNPs or AFRS) by a clinician on the basis of their history and endoscopic and/or CT 
findings, prior to completion of the questionnaire. Controls who had no diagnosis of nasal or 
sinus conditions were recruited from amongst family and friends of those attending ENT 
outpatient clinics (regardless of cause) and from amongst hospital staff, provided they met 
the criteria below. 
Inclusion criteria: 
Criteria for diagnosis of chronic rhinosinusitis (CRS) with or without polyps (EPOS guidelines)1: 
Symptoms must be present for at least 12 weeks and include: 
• nasal blockage/obstruction/congestion and/or nasal discharge (anterior/posterior 
nasal drip) 
• and either facial pain/pressure and/or reduction or loss of sense of smell 
and additionally: 
• endoscopic signs of: polyps and/or mucopurulent discharge primarily from middle 
meatus and/or; oedema/mucosal obstruction primarily in middle meatus 
• and/or CT changes: mucosal changes within the ostiomeatal complex and/or sinuses 
Patients classified as AFRS adhered to either the Bent and Kuhn criteria (see above) or the modified 
Vancouver criteria 16. 
 
Exclusion criteria: 
• Patients unable to comprehend written English. 
• Patients under the age of 18 years. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Sample size calculation and statistical analysis 
The sample size calculation was based on the primary outcome of the study, which was to 
look for common associations between socioeconomic factors and CRS. This is detailed in 
the overview publication of the study 13. For the purposes of these analyses we have used 
descriptive statistics; differences in the rates of medication use between groups were 
assessed by Chi-Squared tests. 
 
Results 
A total of 1,470 participants’ questionnaires were available for analysis; 1249 with CRS and 
221 controls. The age range was 18-102 years (mean 52) with 54% who were male; further 
details of the demographics of the study participants is available in the study overview 
publication13.  
 
Participant flow 
As detailed in figure 1, six participants had incomplete information in the medication section 
of the questionnaire, leaving 1243 participants. A total of 899 had answered positively to 
taking medications with a respective 850 having recorded details of medications taken. As 
the AFRS group was small, we have merged it with the CRSwNPs group and analysed only 
the two main CRS phenotypic groups and the controls. 
 
Missing data 
Subjects identified in figure 1 with missing data were excluded from the analysis in keeping 
with the primary aim of this analysis. Table 1 shows further details of the excluded cases 
based on the text box entries. 
 
Baseline currently used therapy for CRS 
Only 1% of CRS participants reported current use of ND and only 15% of all CRS participants 
reported current use of INCS with a significantly higher uptake in the CRSwNPs group 
(18.4%) than the CRSsNPs group (11.8%) (p=0.002); see table 2. Oral corticosteroid and 
antibiotic use at the time of participants completing the questionnaire was low (1-3%).  
There is no evidence of a difference in social deprivation (as denoted by the index of 
multiple deprivation (IMD) between those prescribed CRS medication and those not (p > 
0.05 for all comparisons; table 2). Patients were also grouped into regional clusters to look 
for geographical variation. Using the following clusters there were no significant signs of 
variation in uptake (p > 0.05): South of England and London, East Anglia, Midlands, North of 
England, Wales, Scotland (table 3). 
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Asthma-related medications 
Table 4 shows the use of asthma-related inhalers that are found to be significantly higher in 
the CRSwNPs group than the CRSsNPs group (16% and 20% in CRSwNPs versus 8% and 9% in 
CRSsNPs for non-steroidal and steroidal inhalers respectively; (p < 0.001). This is however 
much lower than the reported rates of asthma in the two groups (21% and 51%). 
Non-CRS medications 
Analysis of the remaining therapeutic groups noted some key differences between the two 
phenotypic groups as charted in table 5. ACE-inhibitors and α-blockers were significantly more 
prevalent in CRSwNPs (p = 0.04, 0.03) and β-blockers, NSAIDs and opiate analgesics significantly 
more prevalent in CRSsNPs (p < 0.01). 
CRS and Mood disturbances 
The rates of depression and anxiety in CRS from the CRES have been reported elsewhere17, 
however it is pertinent to note that the reported rates of depression are much higher (20% in 
CRSwNPs and 25% in CRSsNPs) than the use of antidepressants themselves (table 6); 7% in 
CRSwNPs and 13% in CRSsNPs. 
Qualitative study 
The qualitative sub-study found that patients reported issues with prescribed treatment in 
primary care 15. Most participants described several courses of different, often ineffective 
treatments, which were not always reviewed.  It was clear that referral to secondary care 
based on a lack of symptomatic response to 3 months of topical treatment did not always 
occur for our participants due to both patient and clinician preferences. 
‘On and off I’ve used nasal sprays, it was a sort of a bit hit and miss really I might think ‘oh it’s a bit 
bad I’ll go to the chemist and get something’’. 
“I’ve now obviously got to do (a nasal spray) (after being seen in secondary care) but I’ve only ever 
had that once… a lot of the time. I would have antibiotics and that would clear it very briefly’ 
Most described several courses of different, often ineffective treatments, which were not 
always reviewed. 
‘Everything I tried was so random.’  
‘I was put onto Betnesol nasal drops, remained on them until last year [without significant benefit. 
Patient had been on this treatment for 40 years].  
There were negative views and misconceptions about topical medications. 
‘The nasal sprays they make it a lot worse... it irritates my eyes and stuff to the point where I’m 
sneezing 100 times and you know it just comes out and I can’t keep it in’ 
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‘If that cost £10,000 for an operation that’s £2,000 for drugs they go cheap route.’ 
Discussion 
 
Key results 
The low prevalence of current use of CRS medication may reflect poor prescribing (including 
advice on how to best use topical treatments), poor adherence to the prescription or poor 
recall. It may also reflect the fact that sprays and rinses are more burdensome to use than 
taking tablets, as described in our qualitative interviews or that they are not seen as ‘proper’ 
medications since they are sprays not tablets 15, 17. Furthermore, it may simply be that 
patients have tried medical therapy but failed to derive significant benefit or did not 
tolerate them, so have stopped taking them. 
Strengths and Limitations 
The study is a large cross-sectional study including a varied population from across the 
United Kingdom. It is the largest research study of CRS in UK to date. In contrast to other 
epidemiological studies in CRS, patients recruited were diagnosed by an 
otorhinolaryngologist according to international guidelines. The study design had some 
limitations, it was a self-reported study which predisposes to recall bias. It is possible that 
some patients may not have considered intranasal medications when asked about 
medication use, however they have reported inhalers so we expect that the impact of this 
on the study findings is small. They may have also not considered ND as a regular 
medication, however both our qualitative work and anecdotal evidence from GP meetings 
suggests that advice regarding ND in primary care is scarce and steam inhalation is more 
often recommended to patients. From qualitative interviews we know that some found ND 
uncomfortable or difficult to integrate into the daily routine, but others are able to tolerate 
it and in fact may find it helpful 18. The fact that the CRES data reflects medication use at one 
moment in time along the patient’s journey, is also a limitation. 
Interpretation 
Looking at the wider picture, one international study demonstrated that one in three CRS 
patients in primary care have poorly controlled symptoms 19; the feedback from our 
participants in the qualitative sub-study also highlighted poor symptom control as a 
problem. The rhinosinusitis commissioning guidelines produced by ENT UK in conjunction 
with the Royal College of Surgeons of England recommend that CRS patients have received 
ND and INCS for 3 months before referral to secondary care 10 and this is derived from the 
European position paper of which there is a summary version for GPs 20. However this low 
use of primary medical treatment is not unique to the UK as shown by a recent Canadian 
study showing the same rate of INCS uptake (20%) and with large geographical variations 11. 
Another study of 60 patients following endoscopic sinus surgery found that overall, 57.4% of 
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patients were non-adherent to their prescribed nasal medication regime 21. Whilst there are 
certainly parallels with our findings in CRES we did not appreciate any regional variations in 
the use of CRS-related medications. 
With regards to non-CRS medications, use of steroid and non-steroid inhalers was higher 
amongst those with CRSwNPs compared to those with CRSsNPs.  This was likely to be due to 
their higher prevalence of asthma. Use of β-blockers and NSAIDs were lower in this group, 
which was also likely to be due to a higher prevalence of asthma (contra-indicated). Use of 
α-blockers was higher amongst CRSwNPs and since it is mostly used for prostatic 
hypertrophy, the difference may be due to a male preponderance in this group. The 
difference in antidepressant use may reflect the fact that facial pain is more common in 
CRSsNPs and correlates with findings that mood and emotional wellbeing are poorer in this 
subgroup, as discussed with the qualitative results and in a separate analysis from CRES of 
mood disturbance in CRS15, 17. 
Generalisability 
Inevitably these patients were referred to secondary care due to failure of primary care 
treatment and doesn’t reflect those who were not referred. Primary care patients who have 
not been referred may all be managing well on INCS and therefore not needing a referral 
whereas those where treatment doesn’t work may be unlikely to continue with treatment. 
However, the population studied in CRES represents those who are typically managed 
within ENT clinics countrywide.  
   Adherence to medical regimens is an important issue, particularly in the management of 
chronic conditions. These findings are consistent with a World Health Organization report, 
which stated that, on average, 50% of patients are not adherent to long-term therapy for 
chronic illnesses. They stated that poor adherence is the primary reason for suboptimal 
clinical benefit in chronic diseases, causing medical and psychosocial complications of the 
disease, reducing quality of life, and wasting health care resources 22. Careful patient 
education may help improve this situation, including reassurance regarding the safety of 
long-term treatment with newer formulations of intranasal steroids that have very low 
systemic bioavailability.  Improved communication from ENT specialists to primary care 
regarding proposed treatment duration is also important.  
Conclusion 
The reported use of baseline medical therapy in CRS appears to be very low. This is likely to 
represent a combination of poor patient compliance, possible perceived lack of 
effectiveness and a lack of familiarity with current guidelines amongst both general 
practitioners and some specialists despite national, European and International guidelines 
for the medical management of CRS in both primary and secondary care. Work is needed to 
understand any barriers to implementing guidelines including disseminating them to all 
practitioners involved in the care of CRS patients and to encourage good compliance with 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
treatment including sound advice on usage of topical medications. Improvement of medical 
management may serve to reduce unnecessary burden on existing healthcare resources for 
this common condition by ensuring timely referral and definitive management when 
needed. 
 
Key points 
• Long term topical therapy is the cornerstone to managing chronic rhinosinusitis. 
• Current levels of compliance with nasal douching and intranasal corticosteroids are likely 
to be poor. 
• Clinicians in both primary and secondary care need to work together to encourage good 
compliance and ensure where possible guidelines are adhered to for best use of 
healthcare resources. 
•  
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Table 1: Medications reported by subgroup 
 
Medication CRSwNPs (n=651) CRSsNPs (n=553) 
ACE Inhibitor 45 (6.91%) 23 (4.16%) 
Alpha Blocker (Inc. Doxazosin) 31 (4.76%) 13 (2.35%) 
Analgesic (Unspecified) 3 (0.46%) 1 (0.18%) 
Antibiotic 10 (1.54%) 16 (2.89%) 
Anticonvulsant 13 (2.00%) 16 (2.89%) 
Antidepressant 46 (7.07%) 75 (13.56%) 
Antihistamines 64 (9.83%) 46 (8.32%) 
Antihypertensive  
(Other – Including Bendrofluazide) 
66 (10.14%) 47 (8.50%) 
Antihypertensive (Unspecified) 18 (2.76%) 13 (2.35%) 
Antiplatelet/Anticoagulant (Inc. Aspirin) 48 (7.37%) 41 (7.41%) 
Beta Blocker 17 (2.61%) 32 (5.79%) 
Diuretic (Exc. Bendrofluazide) 7 (1.08%) 5 (0.90%) 
DMARD/Biologic Agent  
(Inc. Methotrexate) 
6 (0.92%) 4 (0.72%) 
Excluded** 23 (3.53%) 21 (3.80%) 
Hormone Replacement Therapy 6 (0.92%) 12 (2.17%) 
Inhaler (Unspecified) 42 (6.45%) 13 (2.35%) 
Laxative 2 (0.31%) 2 (0.36%) 
Nasal Spray (Unspecified) 8 (1.23%) 14 (2.53%) 
Non-Opiate Analgesic 11 (1.69%) 18 (3.25%) 
Non-Steroid Inhaler 105 (16.13%) 42 (7.59%) 
Non-Steroid Nasal Spray 4 (0.61%) 4 (0.72%) 
NSAID (Exc. Aspirin) 11 (1.69%) 27 (4.88%) 
Opiate Analgesic 20 (3.07%) 35 (6.33%) 
Other* 156 (23.96%) 102 (18.44%) 
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*Other included any medication which did not fit into any particular group. Examples include eye 
drops, skin creams. 
**Reasons for exclusion included: Unknown medication, condition stated rather than medication, 
insufficient information.  
 
  
Proton Pump Inhibitor 63 (9.68%) 60 (10.85%) 
Sinus Rinse 9 (1.38%) 5 (0.90%) 
Statin 88 (13.52%) 65 (11.75%) 
Steroid (Oral) 12 (1.84%) 16 (2.89%) 
Steroid Inhaler 141 (21.66%) 51 (9.22%) 
Steroid Nasal Spray 120 (18.43%) 65 (11.75%) 
Thyroid Hormone 24 (3.69%) 28 (5.06%) 
Vitamin/Mineral Replacement 28 (4.30%) 23 (4.16%) 
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Table 2: CRS-related medication use 
Medication CRSwNPs (n=651) CRSsNPs (n=553) p 
INCS 122 (18.74%) 67 (12.12%) 0.002 
Antihistamines 64 (9.83%) 46 (8.32%) 0.363 
Nasal Spray (Unspecified) 23 (3.53%) 14 (2.53%) 0.317 
Steroid (Oral) 12 (1.84%) 16 (2.89%) 0.2360 
Antibiotic 10 (1.54%) 16 (2.89%) 0.107 
Sinus Rinse  11 (1.69%) 5 (0.9%) 0.234 
 
Table 3: Effect of index of multiple deprivation (IMD) on use of CRS-related medications 
 
Medication Median IMD no use Median IMD use p-value 
INCS 
Antihistamines 15.23 (10.23 – 19.72) 14.89 (9.95 – 18.83) 0.762 
Nasal Spray 
(Unspecified) 
14.99 (10.16 – 19.45) 16.14 (11.30 - 22.45) 0.376 
Steroid (Oral) 14.94 (10.17 – 10.45) 16.86 (11.67 – 22.10) 0.226 
Antibiotic 14.94 (10.16 – 19.64) 16.78 (13.28 – 21.32) 0.353 
Sinus Rinse  14.99 (10.17 – 19.72) 16.70 (11.83 – 17.45) 0.736 
 
 
Table 4: Asthma-related medication use 
Medication
 
CRSwNPs (n=651) CRSsNPs (n=553) p-value 
Steroid Inhaler
 
132 (20.28%) 48 (8.68%)
 
<0.0001
 
Non-Steroid 
Inhaler 
105 (16.13%) 42 (7.59%)
 
<0.0001
 
Inhaler 
(Unspecified)
 
42 (6.45%) 13 (2.35%)
 
0.0007
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Table 5: Other medications with noticeable subgroup variations 
Medication CRSwNPs (n=651)
 
CRSsNPs (n=553)
 
p-value
 
ACE Inhibitor 45 (6.91%) 23 4.16
 
0.040
 
Alpha Blocker  
(Inc. Doxazosin) 
31 4.76 13 2.35
 
0.026
 
Opiate Analgesic 20 3.07 35 6.33
 
0.007
 
Beta Blocker 17 2.61 32 5.79
 
0.005
 
NSAID (Exc. Aspirin) 11 1.69 27 4.88
 
0.002
 
 
Table 6: Comparative reports of depression and antidepressant use 
 Consultation with GP for 
depression (%) 
Antidepressant use (%) 
Controls 15.3 6.3 
CRSsNP 24.6 13.6 
CRSwNP 20.0 7.1 
For more detailed results see Erskine et al17. 
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Figure 1 Legend: Participant flow chart  
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